lomustine has been researched along with Central Nervous System Neoplasm in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "After surgery, patients aged < or = 70 years, with World Health Organization grade 3 or 4 astrocytoma, were randomized to radiotherapy alone (RT) or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV) given at 6-week intervals to a maximum of 12 courses (procarbazine 100 mg/m2 days 1 to 10, lomustine 100 mg/m2 day 1, and vincristine 1." | 9.09 | Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. ( , 2001) |
| "The optimal high-dose methotrexate (HDMTX)-based combination therapy for primary central nervous system lymphoma is unknown." | 8.12 | Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma. ( Avni, B; Gatt, ME; Goldschmidt, N; Grisaro, S; Gural, A; Lavie, D; Lebel, E; Linetski, E; Lossos, A; Makranz, C; Nachmias, B; Rosenberg, S; Saban, R; Shaulov, A; Siegal, T; Vainstein, V; Zimran, E, 2022) |
| "After surgery, patients aged < or = 70 years, with World Health Organization grade 3 or 4 astrocytoma, were randomized to radiotherapy alone (RT) or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV) given at 6-week intervals to a maximum of 12 courses (procarbazine 100 mg/m2 days 1 to 10, lomustine 100 mg/m2 day 1, and vincristine 1." | 5.09 | Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. ( , 2001) |
| " Approximately two thirds of patients with the more aggressive form (anaplastic oligodendroglioma) have shown substantial response to first-line procarbazine/lomustine/vincristine (PCV) therapy." | 4.81 | Chemotherapy for the treatment of oligodendroglial tumors. ( Chinot, O, 2001) |
| "The optimal high-dose methotrexate (HDMTX)-based combination therapy for primary central nervous system lymphoma is unknown." | 4.12 | Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma. ( Avni, B; Gatt, ME; Goldschmidt, N; Grisaro, S; Gural, A; Lavie, D; Lebel, E; Linetski, E; Lossos, A; Makranz, C; Nachmias, B; Rosenberg, S; Saban, R; Shaulov, A; Siegal, T; Vainstein, V; Zimran, E, 2022) |
| "To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU." | 2.74 | High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. ( Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C, 2009) |
| " Parameters were evaluated by age at diagnosis, gender, ethnic origin, pre- and postsurgery Karnofsky Performance Status (KPS) score, limit and amount of surgical resection, histopathologic type, number of chemotherapy courses, time between surgery and radiotherapy, response to combined therapy, and dosage and type of radiotherapy." | 2.70 | Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial. ( Gal, O; Kovner, F; Ron, IG; Vishne, TH, 2002) |
| "Significant advances in the treatment of medulloblastoma and primitive neuroectodermal tumors have been made in the past three decades." | 2.42 | Medulloblastomas and central nervous system primitive neuroectodermal tumors. ( McLean, TW, 2003) |
| " For each tumor-derived cell culture, a complete dose-response curve was established for each chemotherapeutic agent tested." | 1.32 | Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents. ( Burholt, DR; Donovan, M; George, LD; Kornblith, PL; Marsh, JW, 2004) |
| "However, the presence of metastases separate from the pituitary in the central nervous system or at a distance is necessary to designate pituitary tumors as carcinomas, i." | 1.30 | The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. ( Besser, GM; Grossman, AB; Kaltsas, GA; Monson, JP; Mukherjee, JJ; Plowman, PN, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Lebel, E | 1 |
| Goldschmidt, N | 1 |
| Siegal, T | 1 |
| Lossos, A | 1 |
| Rosenberg, S | 1 |
| Makranz, C | 1 |
| Linetski, E | 1 |
| Gatt, ME | 1 |
| Gural, A | 1 |
| Saban, R | 1 |
| Lavie, D | 1 |
| Vainstein, V | 1 |
| Zimran, E | 1 |
| Avni, B | 1 |
| Grisaro, S | 1 |
| Shaulov, A | 1 |
| Nachmias, B | 1 |
| Illerhaus, G | 2 |
| Marks, R | 1 |
| Müller, F | 1 |
| Ihorst, G | 2 |
| Feuerhake, F | 1 |
| Deckert, M | 1 |
| Ostertag, C | 1 |
| Finke, J | 2 |
| Fritsch, K | 1 |
| Kasenda, B | 1 |
| Hader, C | 1 |
| Nikkhah, G | 1 |
| Prinz, M | 1 |
| Haug, V | 1 |
| Haug, S | 1 |
| Sierra Del Rio, M | 1 |
| Ricard, D | 1 |
| Houillier, C | 1 |
| Navarro, S | 1 |
| Gonzalez-Aguilar, A | 1 |
| Idbaih, A | 1 |
| Kaloshi, G | 1 |
| Elhallani, S | 1 |
| Omuro, A | 1 |
| Choquet, S | 1 |
| Soussain, C | 1 |
| Hoang-Xuan, K | 2 |
| Ater, JL | 1 |
| Zhou, T | 1 |
| Holmes, E | 1 |
| Mazewski, CM | 1 |
| Booth, TN | 1 |
| Freyer, DR | 1 |
| Lazarus, KH | 1 |
| Packer, RJ | 1 |
| Prados, M | 1 |
| Sposto, R | 1 |
| Vezina, G | 1 |
| Wisoff, JH | 1 |
| Pollack, IF | 1 |
| Brandes, AA | 1 |
| Vastola, F | 1 |
| Basso, U | 1 |
| Berti, F | 1 |
| Pinna, G | 1 |
| Rotilio, A | 1 |
| Gardiman, M | 1 |
| Scienza, R | 1 |
| Monfardini, S | 1 |
| Ermani, M | 1 |
| Taillandier, L | 1 |
| Chinot, O | 2 |
| Soubeyran, P | 1 |
| Bogdhan, U | 1 |
| Hildebrand, J | 1 |
| Frenay, M | 1 |
| De Beule, N | 1 |
| Delattre, JY | 1 |
| Baron, B | 1 |
| McLean, TW | 1 |
| Marsh, JW | 1 |
| Donovan, M | 1 |
| Burholt, DR | 1 |
| George, LD | 1 |
| Kornblith, PL | 1 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Galanis, E | 1 |
| Kaltsas, GA | 1 |
| Mukherjee, JJ | 1 |
| Plowman, PN | 1 |
| Monson, JP | 1 |
| Grossman, AB | 1 |
| Besser, GM | 1 |
| Herrlinger, U | 1 |
| Brugger, W | 1 |
| Bamberg, M | 1 |
| Küker, W | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Chamberlain, MC | 2 |
| Ron, IG | 1 |
| Gal, O | 1 |
| Vishne, TH | 1 |
| Kovner, F | 1 |
| Kochi, M | 1 |
| Ushio, Y | 1 |
| Boiardi, A | 1 |
| Silvani, A | 1 |
| Milanesi, I | 1 |
| Broggi, G | 1 |
| Fariselli, L | 1 |
| Levin, VA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy[NCT00989352] | Phase 2 | 56 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old[NCT00002944] | Phase 3 | 428 participants (Actual) | Interventional | 1997-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lomustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Medulloblastomas and central nervous system primitive neuroectodermal tumors.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Cerebellar Neoplasms; Cisplatin; Cyclophosp | 2003 |
Chemotherapy for the treatment of oligodendroglial tumors.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous S | 2001 |
[Chemo-radiotherapy for malignant brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System | 2002 |
10 trials available for lomustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Comb | 2009 |
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2011 |
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Central Nervous System | 2012 |
A prospective study on glioblastoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mod | 2003 |
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Belgium; Biops | 2003 |
PCV salvage chemotherapy for recurrent primary CNS lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Huma | 2000 |
Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Central Nervous System Neo | 2001 |
Treatment of intracranial metastatic esthesioneuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Esthe | 2002 |
Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Central | 2002 |
Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Glioblastoma; Huma | 1992 |
6 other studies available for lomustine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl | 2022 |
Prophylactic intrathecal chemotherapy in primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2012 |
Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkyl | 2004 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1998 |
Primary central nervous system lymphoma: a role for adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 1992 |